Fraudulent care messages drive stress and confusion, pushing brands to rethink patient communication strategies.
India’s GLP-1 rollout next month signals tougher pricing ahead for GLP-1 brands.
Rising FDA enforcement pushes drugmakers to revisit messaging and risk framing.
Doctors must reassert personalized nutrition advice, while food brands should highlight their better-for-you offerings.
Convenience and drug savings will attract some consumers, but Amazon hasn’t yet been able to disrupt the pharmacy space.
The FDA denied an application for its flu vaccine, deepening regulatory doubt and complicating forecasts for vaccine-driven revenue growth.
Consumers show cautious interest, but only if tools are clinically validated, transparent, and privacy secure.
Novo’s lawsuit and regulator warnings signal a crackdown on compounded GLP-1s across telehealth.
Aetna is finally finding its footing, managing medical costs more effectively, even as industry-wide pressures remain.
Its recent Pfizer and TrumpRx partnerships show how pharma companies are betting on D2C distribution and consumer-facing pricing.
Big linear TV won’t wow all viewers, but the massive reach can still drive research, provider talks, and care.
The cash-pay discount hub will offer fewer drugs than GoodRx and have limited reach, but drugmakers must still promote it to drive prescription volumes, especially for uninsured drugs.
Apple isn’t abandoning AI-powered health guidance, but it’s likely holding back until the tech is useful enough to deliver real value.
Novo’s Big Game spot can help reinforce the Wegovy pill’s credibility against copycat compounded versions.
Midi Health’s growth shows sustained focus on women’s care can fuel digital health trust and scale.
An FTC settlement and newly passed legislation in Congress scraps rebate tactics and formulary bias, chipping away at PBM pricing power.
Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.
Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.
Most Americans are wary of their use in healthcare, but supervised medical use is starting to feel acceptable.
Costs will shape 2026 midterm votes, with both parties targeting insurers and pharma to lower costs. The industry has a chance to defend its role—and show real affordability gains.